Cell line · CVCL_1108
Papers44
1 to 20 of 44
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| A First-in-Class LZK Inhibitor Suppresses Tumor Growth and Potentiates EGFR and PI3K Pathway Blockade in Head and Neck and Esophageal Cancers. | bioRxiv | 2026 | Its Methods give the RRID and name the line | PubMed | |
| NLRX1 contributes to immunotherapeutic resistance of head and neck squamous cell carcinoma by suppressing type I interferon pathway. | Front Immunol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Genome-wide CRISPR screen identifies AMBRA1 as a potential biomarker of response to platinum-based therapies in oral squamous cell carcinomas. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Suppression of AKT Activation through LZK Inhibition Limits Tumor Growth in Esophageal and Head and Neck Cancers. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Genetically targeted mTORC1 inhibitor reveals transcriptional control by nuclear mTORC1. | Nat Chem Biol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Hypoxia Induces a Mitotic Survival Advantage After Radiotherapy in Head and Neck Cancer Cells. | Int J Cancer | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Genome-wide CRISPR Screening Reveals a PKA-Driven Resistance Mechanism to Metformin for Oral Cancer Prevention That Can Be Exploited by Combination with NSAIDs. | Cancer Prev Res (Phila) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex. | Cancer Discov | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Genome-Wide CRISPR Screening Reveals That mTOR Inhibition Initiates Ferritinophagy and Ferroptosis in Head and Neck Cancer. | Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Enhancing the Efficacy of CAR-T Cell Production Using BX795 and Rosuvastatin in a Serum-Free Medium. | Int J Mol Sci | 2025 | Its Methods give the RRID and name the line | PubMed | |
| De Novo Serine Synthesis Is a Metabolic Vulnerability That Can Be Exploited to Overcome Sunitinib Resistance in Advanced Renal Cell Carcinoma. | Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| YAP-driven malignant reprogramming of oral epithelial stem cells at single cell resolution. | Nat Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| SKA1 promotes oncogenic properties in oral dysplasia and oral squamous cell carcinoma, and augments resistance to radiotherapy. | Mol Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Pro-apoptotic and anti-proliferative activities of cassane diterpenoids on squamous carcinoma cells: An in vitro and in silico study. | Toxicol Rep | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Inhibition of ATM or ATR in combination with hypo-fractionated radiotherapy leads to a different immunophenotype on transcript and protein level in HNSCC. | Front Oncol | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Effective Radiosensitization of HNSCC Cell Lines by DNA-PKcs Inhibitor AZD7648 and PARP Inhibitors Talazoparib and Niraparib. | Int J Mol Sci | 2024 | Its Methods give the RRID and name the line | PubMed | |
| CLU (clusterin) and PPARGC1A/PGC1α coordinately control mitophagy and mitochondrial biogenesis for oral cancer cell survival. | Autophagy | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Epigenetic Targeting to Overcome Radioresistance in Head and Neck Cancer. | Cancers (Basel) | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Irreversible cell cycle exit associated with senescence is mediated by constitutive MYC degradation. | Cell Rep | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Activation of the EGFR/PI3K/AKT pathway limits the efficacy of trametinib treatment in head and neck cancer. | Mol Oncol | 2023 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1108/papers